DMD Bio-Rad Microplate Reader

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hijazi, Y.
Right arrow Articles by Boulieu, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hijazi, Y.
Right arrow Articles by Boulieu, R.

Vol. 30, Issue 7, 853-858, July 2002

Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N-Demethylation of Ketamine in Human Liver Microsomes

Youssef Hijazi and Roselyne Boulieu

Université Claude Bernard Lyon 1, Département de Pharmacie Clinique de Pharmacocinétique et d'Evaluation du Médicament; and Hôpital Neuro-Cardiologique, Laboratoire de Dosage des Médicaments, Lyon Cedex, France

Ketamine is a widely used drug for its anesthetic and analgesic properties; it is also considered as a drug of abuse, as many cases of ketamine illegal consumption were reported. Ketamine is N-demethylated by liver microsomal cytochrome P450 into norketamine. The identification of the enzymes responsible for ketamine metabolism is of great importance in clinical practice. In the present study, we investigated the metabolism of ketamine in human liver microsomes at clinically relevant concentrations. Liver to plasma concentration ratio of ketamine was taken into consideration. Pooled human liver microsomes and human lymphoblast-expressed P450 isoforms were used. N-demethylation of ketamine was correlated with nifedipine oxidase activity (CYP3A4-specific marker reaction), and it was also correlated with S-mephenytoin N-demethylase activity (CYP2B6-specific marker reaction). Orphenadrine, a specific inhibitor to CYP2B6, and ketoconazole, a specific inhibitor to CYP3A4, inhibited the N-demethylation of ketamine in human liver microsomes. In human lymphoblast-expressed P450, the activities of CYP2B6 were higher than those of CYP3A4 and CYP2C9 at three concentrations of ketamine, 0.005, 0.05, and 0.5 mM. When these results were extrapolated using the average relative content of these P450 isoforms in human liver, CYP3A4 was the major enzyme involved in ketamine N-demethylation. The present study demonstrates that CYP3A4 is the principal enzyme responsible for ketamine N-demethylation in human liver microsomes and that CYP2B6 and CYP2C9 have a minor contribution to ketamine N-demethylation at therapeutic concentrations of the drug.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Br J AnaesthHome page
M. P. Larenza, M. F. Landoni, O. L. Levionnois, M. Knobloch, P. W. Kronen, R. Theurillat, U. Schatzmann, and W. Thormann
Stereoselective pharmacokinetics of ketamine and norketamine after racemic ketamine or S-ketamine administration during isoflurane anaesthesia in Shetland ponies
Br. J. Anaesth., February 1, 2007; 98(2): 204 - 212.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
R. L. Walsky, A. V. Astuccio, and R. S. Obach
Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6.
J. Clin. Pharmacol., December 1, 2006; 46(12): 1426 - 1438.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. L. F. Rehmel, J. A. Eckstein, N. A. Farid, J. B. Heim, S. C. Kasper, A. Kurihara, S. A. Wrighton, and B. J. Ring
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450
Drug Metab. Dispos., April 1, 2006; 34(4): 600 - 607.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. L. Williams, D. E. Mager, H. Parenteau, G. Gudi, T. S. Tracy, M. Mulheran, and I. W. Wainer
EFFECTS OF PROTEIN CALORIE MALNUTRITION ON THE PHARMACOKINETICS OF KETAMINE IN RATS
Drug Metab. Dispos., August 1, 2004; 32(8): 786 - 793.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
Y. Hijazi, C. Bodonian, M. Bolon, F. Salord, and R. Boulieu
Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury
Br. J. Anaesth., February 1, 2003; 90(2): 155 - 160.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.